Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Bayer
Boehringer Ingelheim
Compass Therapeutics
Compass Therapeutics
Novartis
M.D. Anderson Cancer Center
Genentech, Inc.
National Cancer Institute (NCI)
The Methodist Hospital Research Institute
OncoC4, Inc.
USWM, LLC (dba US WorldMeds)
KaliVir Immunotherapeutics
Pfizer
Pfizer
Sotio Biotech Inc.
Pfizer
Pfizer
Pfizer
M.D. Anderson Cancer Center
Mayo Clinic
Dragonfly Therapeutics
Stanford University
Merck Sharp & Dohme LLC
ViroMissile, Inc.
Erasca, Inc.
Pfizer
Tizona Therapeutics, Inc
MacroGenics
Adaptimmune
City of Hope Medical Center
Novartis
AbbVie
AgonOx, Inc.
Innate Pharma
Novartis
Pierre Fabre Medicament
OncoNano Medicine, Inc.
Degron Therapeutics Co.
Memorial Sloan Kettering Cancer Center
NeoTX Therapeutics Ltd.
AccSalus Biosciences, Inc.
LG Chem
West China Hospital
HiFiBiO Therapeutics
Petrov, Andrey
TScan Therapeutics, Inc.
Bolt Biotherapeutics, Inc.
Incyte Corporation
HiFiBiO Therapeutics